About this policy
The comment period for the MolDX: Decipher ® Biopsy Prostate Cancer Classifier Assay for Men with Favorable Intermediate Risk Disease DL38303 Local Coverage Determination (LCD) began on 10/30/19 and ended on 12/14/19. The notice period for L38303 begins on 9/24/2020 and will become effective on 11/8/2020. The title of the LCD was revised from MolDX: Decipher ® Biopsy Prostate Cancer Classifier Assay for Men with Favorable Intermediate Risk Disease to MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease. The comments below were received from the provider community.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.